Antony Suresh J, Singh Joya, de Jesus Mikhail, Lance Jessalyn
Texas Tech University Health Sciences, El Paso, TX, United States.
Burrell College of OsteoPathic Medicine, Las Cruces, NM, United States.
IDCases. 2020 Jun 26;21:e00888. doi: 10.1016/j.idcr.2020.e00888. eCollection 2020.
As of May 14, 2020, the World Health Organization has reported approximately 4.3 million cases of the novel Coronavirus Disease (COVID-19) with approximately 294,046 deaths worldwide [1]. Solid organ transplant recipients who are on chronic immunosuppressants fall within a special population of COVID-19 patients since they are more susceptible to complications secondary to COVID-19. Currently, we do not have data on treating COVID-19 patients with solid organ transplants with tocilizumab, an interleukin-6 (IL-6) inhibitor. We report a case of COVID-19 in a patient with a kidney and liver transplant and discuss the early use of tocilizumab to prevent the cytokine storm and attempt to reduce the likelihood of progression to Acute Respiratory Distress Syndrome (ARDS). In addition, we present other COVID-19 related transplant cases reported in the literature outlining the presenting clinical signs and outcomes.
截至2020年5月14日，世界卫生组织报告全球新型冠状病毒病（COVID-19）病例约430万例，死亡约294,046例[1]。接受慢性免疫抑制剂治疗的实体器官移植受者属于COVID-19患者的特殊人群，因为他们更容易发生COVID-19继发的并发症。目前，我们没有关于使用白细胞介素-6（IL-6）抑制剂托珠单抗治疗实体器官移植COVID-19患者的数据。我们报告了1例肾肝移植患者的COVID-19病例，并讨论了早期使用托珠单抗预防细胞因子风暴以及试图降低进展为急性呼吸窘迫综合征（ARDS）可能性的情况。此外，我们还介绍了文献中报道的其他与COVID-19相关的移植病例，概述了呈现的临床症状和结果。
